Vascular endothelial growth factor-A as a promising therapeutic target for the management of psoriasis

Andrea Luengas Martinez, Jonathan Hardman-Smart, Ralf Paus, Helen Young

Research output: Contribution to journalArticlepeer-review


Vascular endothelial growth factor-A (VEGF-A), the main angiogenic mediator, plays a critical role in the pathogenesis of several inflammatory immune-mediated diseases, including psoriasis. Even though anti-angiogenic therapies, such as VEGF inhibitors, are licensed for the treatment of various cancers and eye disease, VEGF-targeting interventions are not part of current psoriasis therapy. In this Viewpoint essay, we argue that the existing preclinical research evidence on the role of VEGF-A in the pathogenesis of psoriasis as well as clinical observations in patients that have experienced psoriasis remission during oncological anti-VEGF-A therapy, strongly suggest to systematically explore angiogenesis targeting also in the management of psoriasis. We also point out that some psoriasis therapies decrease circulating levels of VEGF-A and normalise the psoriasis-associated vascular pathology in the papillary dermis of plaques of psoriasis, and that a subset of patients with constitutionally high levels of VEGF-A may benefit most from the anti-angiogenic therapy we advocate here. Given that novel, well-targeted personalised medicine therapies for the development of psoriasis need to be developed, we explore the hypothesis that VEGF-A and signalling through its receptors constitute a promising target for therapeutic intervention in the future management of psoriasis.
Original languageEnglish
Pages (from-to)687-698
Number of pages12
JournalExperimental Dermatology
Issue number8
Publication statusPublished - 12 Jul 2020


Dive into the research topics of 'Vascular endothelial growth factor-A as a promising therapeutic target for the management of psoriasis'. Together they form a unique fingerprint.

Cite this